Organ Protection
Conditions
Keywords
Postoperative cognitive dysfunction, Lidocaine, Brain-derived neurotrophic factor, Nerve growth factor, miRNA-206, miRNA-98
Brief summary
The purpose of this study is to investigate the efficacy of intravenous lidocaine on BDNF, NGF, miRNA-206 and miRNA-98 in serum in elderly patients undergoing abdominal surgery under general anesthesia.
Detailed description
Postoperative cognitive dysfunction (POCD) is a major complication following surgeries and anesthesia, especially in elderly individuals. Lidocaine, an inexpensive, widely available, and relatively safe compound, is a local anesthetic that readily crosses the blood-brain barrier. Intravenous lidocaine can reduce the incidence of POCD. However, the mechanism is still unclear. Brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), which are regulated by miRNA-206 and miRNA-98 respectively, play a key role in learning, memory, and cognition. Previous studies have shown that the levels of BDNF and NGF can be improved by lidocaine. The objective of this study is to investigate the efficacy of intravenous lidocaine on the incidence of early POCD, and the levels of BDNF, NGF, miRNA-206 and miRNA-98 in elderly patients undergoing abdominal surgery under general anesthesia.
Interventions
DRUGLidocaine
Intravenous bolus of 1.5 mg/kg of lidocaine followed by a continuous infusion of 3.0 mg/kg for the frst hour, 1.5 mg/kg for the second hour, 0.7 mg/kg until the end of the surgery
OTHERNormal saline (NS)
Patients are received equal volumes of saline intravenously until the end of the surgery
Sponsors
General Hospital of Ningxia Medical University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Caregiver)
Eligibility
Sex/Gender
ALL
Age
65 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Patients were scheduled by following abdominal surgery under general anesthesia * Aged 65 - 80 years * ASA physical status Ⅱ-Ⅲ
Exclusion criteria
* Severe heart, pulmonary, hepatic and renal insufficiency * History of neurological diseases (including Alzheimer's disease and stroke history) * Psychological disorder, and drug or alcohol abuse * History of anesthesia and surgery * psychiatric illness * Unwillingness to comply with the protocol or procedures * Allergic to lidocaine * Mini-Mental State Examination (MMSE) score\<23 before surgery
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes from Baseline BDNF at 1, 3 days after surgery | at preoperation,1 and 3 days postoperation | Venous blood samples were sampled before anaesthesia induction and 1, 3 days after surgery for the BDNF by using Enzyme-linked immunosorbent assay. |
| Changes from Baseline NGF at 1, 3 days after surgery | at preoperation,1 and 3 days postoperation | Venous blood samples were sampled before anaesthesia induction and 1, 3 days after surgery for the NGF by using Enzyme-linked immunosorbent assay. |
| Changes from Baseline miRNA-206 at 1, 3 days after surgery | at preoperation,1 and 3 days postoperation | Venous blood samples were sampled before anaesthesia induction and 1, 3 days after surgery for the miRNA-206 by using PCR. |
| Changes from Baseline miRNA-98 at 1, 3 days after surgery | at preoperation,1 and 3 days postoperation | Venous blood samples were sampled before anaesthesia induction and 1, 3 days after surgery for the miRNA-98 by using PCR. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes from Baseline mini-mental state examination (MMSE) at 1, 3 days after surgery | at preoperation,1 and 3 days postoperation | MMSE was performed |
Other
| Measure | Time frame | Description |
|---|---|---|
| Postoperative cognitive dysfunction (POCD) | at preoperation,1 and 3 days postoperation | the incidence of POCD |
Outcome results
None listed